BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at Biotechnology Industry Organization (BIO) International Convention in Chicago, April 22-25


4/18/2013 7:02:57 AM

LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity. One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology.

Because Replikins is leveraging proprietary software techniques to isolate targeted regions in the virus, combined with recent advances in manufacturing synthetic peptides, the company and its partners are able to provide rapid turnaround of vaccine candidates based on early data emerging from disease outbreaks. This approach stands in marked contrast to projections by other companies of delays of seven months or longer before vaccines can be made available, and makes it possible to consider effective public health responses to disease outbreaks while they are still at an early stage.

Replikins will provide details of the technology and is seeking partnerships at the BIO International Convention April 22nd-25th at its booth #3456, McCormick Place, Chicago.

The technique used to create Replikins' new synthetic vaccine candidates is similar to those the company used in manufacturing a successful Replikins H5N1 "bird flu" vaccine in chickens in a paper published in 2009. That vaccine was produced in 7 days, shipped freeze-dried, and administered via the respiratory tract. Significantly, in addition to stopping the virus in the chickens, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.

Contact: Dr. Samuel Bogoch, 646-320-5910, Email

References:

1. Nature Precedings. Bogoch et al, doi:10.1038/npre.2012.6952.1

(see also seven additional Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.

2. www.replikins.com

3. Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)

4. Jackwood et al. Avian Diseases 53(4): 613617, 2009

This press release was issued through eReleasesĀ® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Replikins



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES